A Open-label, Randomized, Parallel, Phase III Trial to Evaluate the Efficacy and Safety of Genexol-PM Compared to Genexol (Conventional Paclitaxel With Cremorphor EL) in Subjects With Recurrent or Metastatic Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 04 May 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Samyang Biopharmaceuticals Corporation
- 27 Apr 2017 Status changed from active, no longer recruiting to completed.
- 01 Jul 2013 Interim results presented at the 4th International Nanomedicine Conference in Sydney Australia, according to a media release from Sorrento Therapeutics and IGDRASOL.
- 13 May 2013 Comprehensive data analyses will be presented at future medical conferences, according to a Sorrento Therapeutics and IgDraSol media release.